313 related articles for article (PubMed ID: 32902200)
1. Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan.
Kishi T; Yoshimura R; Sakuma K; Okuya M; Iwata N
Neuropsychopharmacol Rep; 2020 Dec; 40(4):417-422. PubMed ID: 32902200
[TBL] [Abstract][Full Text] [Related]
2. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis.
Ostacher M; Ng-Mak D; Patel P; Ntais D; Schlueter M; Loebel A
World J Biol Psychiatry; 2018 Dec; 19(8):586-601. PubMed ID: 28264635
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of lurasidone vs quetiapine extended-release (XR) in patients with bipolar depression.
Rajagopalan K; Meyer K; O'Day K; Denno M; Loebel A
J Med Econ; 2015; 18(10):821-7. PubMed ID: 25985265
[TBL] [Abstract][Full Text] [Related]
4. Comparison of quetiapine immediate- and extended-release formulations for bipolar depression: A systematic review and network meta-analysis of double-blind, randomized placebo-controlled trials.
Kishi T; Ikuta T; Sakuma K; Matsuda Y; Iwata N
J Psychiatr Res; 2019 Aug; 115():121-128. PubMed ID: 31128502
[TBL] [Abstract][Full Text] [Related]
5. Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression.
Murasaki M; Koyama T; Kanba S; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
Psychopharmacology (Berl); 2018 Oct; 235(10):2859-2869. PubMed ID: 30069587
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis.
Kadakia A; Dembek C; Heller V; Singh R; Uyei J; Hagi K; Nosaka T; Loebel A
BMC Psychiatry; 2021 May; 21(1):249. PubMed ID: 33975574
[TBL] [Abstract][Full Text] [Related]
7. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L; Ketter TA; Cucchiaro J; Loebel A
J Affect Disord; 2014 Feb; 155():20-7. PubMed ID: 24246116
[TBL] [Abstract][Full Text] [Related]
8. Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression.
Kanba S; Murasaki M; Koyama T; Takeuchi M; Shimizu Y; Arita E; Kuroishi K; Takeuchi M; Kamei S
BMC Psychiatry; 2019 Jun; 19(1):198. PubMed ID: 31242884
[TBL] [Abstract][Full Text] [Related]
9. Quetiapine: a review of its use in the management of bipolar depression.
Sanford M; Keating GM
CNS Drugs; 2012 May; 26(5):435-60. PubMed ID: 22519923
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis.
Kishi T; Ikuta T; Matsuda Y; Iwata N
Neuropsychopharmacol Rep; 2019 Sep; 39(3):256-259. PubMed ID: 31283865
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis.
Li S; Xu C; Hu S; Lai J
Eur Psychiatry; 2024 Mar; 67(1):e29. PubMed ID: 38487836
[TBL] [Abstract][Full Text] [Related]
12. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
Citrome L
Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression.
DelBello MP; Kadakia A; Heller V; Singh R; Hagi K; Nosaka T; Loebel A
J Am Acad Child Adolesc Psychiatry; 2022 Feb; 61(2):243-254. PubMed ID: 34420839
[TBL] [Abstract][Full Text] [Related]
14. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan.
Kishi T; Nosaka T; Sakuma K; Okuya M; Iwata N
Neuropsychopharmacol Rep; 2020 Sep; 40(3):314-322. PubMed ID: 32767739
[TBL] [Abstract][Full Text] [Related]
16. Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat.
Gao K; Yuan C; Wu R; Chen J; Wang Z; Fang Y; Calabrese JR
Neurosci Bull; 2015 Oct; 31(5):572-88. PubMed ID: 26024955
[TBL] [Abstract][Full Text] [Related]
17. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
[TBL] [Abstract][Full Text] [Related]
18. Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials.
Bai Y; Yang H; Chen G; Gao K
J Clin Psychopharmacol; 2020; 40(2):167-179. PubMed ID: 32134852
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of quetiapine extended release monotherapy in bipolar depression: a multi-center, randomized, double-blind, placebo-controlled trial.
Li H; Gu N; Zhang H; Wang G; Tan Q; Yang F; Ning Y; Zhang H; Lu Z; Xu X; Shi J; Gao C; Li L; Zhang K; Tian H; Wang X; Li K; Li H; Xu Y; Xie S; Yu X
Psychopharmacology (Berl); 2016 Apr; 233(7):1289-97. PubMed ID: 26911380
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of quetiapine XR vs. placebo as concomitant treatment to mood stabilizers in the control of subthreshold symptoms of bipolar disorder: Results from a pilot, randomized controlled trial.
Garriga M; Solé E; González-Pinto A; Selva-Vera G; Arranz B; Amann BL; Saiz-Ruiz J; Pérez-Blanco J; Vieta E
Eur Neuropsychopharmacol; 2017 Oct; 27(10):959-969. PubMed ID: 28882405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
